Signia Capital Management Increased Its Gamestop New (GME) Position; Marinus Pharmaceuticals (MRNS) Shorts Up By 9.97%

GameStop Corp. (NYSE:GME) Logo

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) had an increase of 9.97% in short interest. MRNS’s SI was 2.89M shares in March as released by FINRA. Its up 9.97% from 2.63 million shares previously. With 622,300 avg volume, 5 days are for Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s short sellers to cover MRNS’s short positions. The stock increased 1.06% or $0.04 during the last trading session, reaching $3.83. About 1.42M shares traded or 58.03% up from the average. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 28.66% since March 17, 2018 and is downtrending. It has underperformed by 33.03% the S&P500. Some Historical MRNS News: 06/03/2018 – MARINUS PHARMACEUTICALS – BELIEVE CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 TO ENABLE FUNDING OPER EXPENSES AND CAPEX NEEDS INTO 2020; 07/03/2018 – STAT Plus: Marinus Pharma finds the biotech imitation game can only last so long; 06/03/2018 – $MRNS increased enrollment in PPD study, data readout pushed back to 3Q18; 23/04/2018 – DJ Marinus Pharmaceuticals Inc, Inst Holders, 1Q 2018 (MRNS); 06/03/2018 Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results; 02/05/2018 – Marinus Pharmaceuticals 1Q Loss/Shr 15c; 14/05/2018 – Marinus Pharma Presenting at UBS Conference May 21; 15/05/2018 – GMT Capital Buys New 3.1% Position in Marinus Pharma; 15/05/2018 – Three Bays Capital Buys New 2.3% Position in Marinus Pharma; 24/05/2018 – Marinus Pharma Closes Above 200-Day Moving Average: Technicals

Signia Capital Management Llc increased Gamestop Corp New (GME) stake by 438.34% reported in 2018Q4 SEC filing. Signia Capital Management Llc acquired 373,464 shares as Gamestop Corp New (GME)’s stock declined 22.92%. The Signia Capital Management Llc holds 458,663 shares with $5.79M value, up from 85,199 last quarter. Gamestop Corp New now has $1.13B valuation. The stock increased 1.00% or $0.11 during the last trading session, reaching $11.06. About 3.54M shares traded. GameStop Corp. (NYSE:GME) has declined 27.55% since March 17, 2018 and is downtrending. It has underperformed by 31.92% the S&P500. Some Historical GME News: 28/03/2018 – GameStop’s Results, Earnings Forecast Beat Projections — Earnings Review; 28/03/2018 – GameStop 4Q Loss $105.9M; 11/05/2018 – GameStop CEO Michael Mauler Resigns for Personal Reasons; 26/03/2018 – GameStop Earnings: The New CEO Has Plenty to Do — Barrons.com; 16/05/2018 – GAMESTOP CONFIRMS RECEIVING TIGER MANAGEMENT LETTER: CNBC; 11/05/2018 – GameStop: Surprise CEO Departure Is Another Stumbling Block — Barrons.com; 29/03/2018 – GameStop: A Tough Outlook Leads to a Sharp Fall — Barrons.com; 11/05/2018 – GameStop Had Named Mauler CEO in February; 16/05/2018 – TIGER MGMT IS AID TO URGE GAMESTOP STRATEGIC REVIEW: CNBC; 28/03/2018 – GAMESTOP CORP SEES 2018 CAPITAL EXPENDITURES $110.0 MLN TO $120.0 MLN

More notable recent GameStop Corp. (NYSE:GME) news were published by: Seekingalpha.com which released: “GameStop -5% after BAML cut – Seeking Alpha” on March 08, 2019, also 247Wallst.com with their article: “Will It Take a Proxy Fight to Finally Turn GameStop Around? – 24/7 Wall St.” published on March 14, 2019, Fool.com published: “Can Activist Investors Force GameStop to Evolve? – The Motley Fool” on March 16, 2019. More interesting news about GameStop Corp. (NYSE:GME) were released by: Investorplace.com and their article: “Why GameStop Stock Can Survive the Streaming Revolution – Investorplace.com” published on March 05, 2019 as well as Globenewswire.com‘s news article titled: “Cha-Ching: GameStop Offers Savings Relief with Hot Deals – GlobeNewswire” with publication date: February 21, 2019.

Investors sentiment increased to 1.02 in Q4 2018. Its up 0.22, from 0.8 in 2018Q3. It is positive, as 30 investors sold GME shares while 74 reduced holdings. 42 funds opened positions while 64 raised stakes. 101.05 million shares or 3.25% more from 97.87 million shares in 2018Q3 were reported. Glenmede Na owns 886 shares. Vanguard Group Inc holds 0.01% or 10.36M shares in its portfolio. Pnc Serv Group, Pennsylvania-based fund reported 5,035 shares. Moreover, Lpl Ltd Liability Corp has 0% invested in GameStop Corp. (NYSE:GME) for 23,658 shares. Mason Street, Wisconsin-based fund reported 31,660 shares. Goldman Sachs Gp Inc stated it has 0% in GameStop Corp. (NYSE:GME). Swiss Bankshares owns 0% invested in GameStop Corp. (NYSE:GME) for 180,182 shares. Credit Suisse Ag reported 0% of its portfolio in GameStop Corp. (NYSE:GME). American Group Inc Inc invested 0.01% in GameStop Corp. (NYSE:GME). Financial Pro invested in 0% or 5 shares. Axa reported 243,300 shares. Barrow Hanley Mewhinney & Strauss Lc holds 0.01% or 233,027 shares in its portfolio. Moreover, Moody Financial Bank Trust Division has 0% invested in GameStop Corp. (NYSE:GME). Parametric Ltd Liability holds 1.13 million shares. Huntington Natl Bank holds 1 shares.

Among 3 analysts covering GameStop (NYSE:GME), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. GameStop had 4 analyst reports since November 26, 2018 according to SRatingsIntel. The rating was downgraded by Bank of America to “Underperform” on Friday, March 8. The stock has “Hold” rating by Loop Capital Markets on Tuesday, March 5. The rating was downgraded by Robert W. Baird on Tuesday, January 29 to “Neutral”. The rating was upgraded by Bank of America to “Neutral” on Monday, November 26.

Investors sentiment decreased to 0.98 in 2018 Q4. Its down 0.82, from 1.8 in 2018Q3. It fall, as 20 investors sold Marinus Pharmaceuticals, Inc. shares while 20 reduced holdings. 19 funds opened positions while 20 raised stakes. 26.47 million shares or 18.54% more from 22.33 million shares in 2018Q3 were reported. Moreover, Spark Inv Management Llc has 0.03% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 145,500 shares. Tekla Capital Ltd Liability Corp invested in 0.09% or 755,776 shares. Geode Capital Mngmt Lc holds 464,483 shares or 0% of its portfolio. Tiaa Cref Invest Management Lc holds 149,898 shares. 6,514 are held by Royal Retail Bank Of Canada. Granite Point Capital Mgmt Lp has invested 1.54% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Bridgeway Mngmt holds 0% or 71,706 shares in its portfolio. Partner Investment Mngmt Lp invested 0.01% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Moreover, Blackrock has 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Arrowmark Colorado Holdg Ltd Com has 10,735 shares. Wells Fargo & Communications Mn has 17,622 shares. Marshall Wace Llp, United Kingdom-based fund reported 9,466 shares. Alpine Management Limited Liability Co invested in 0.07% or 89,096 shares. 642 are owned by Bnp Paribas Arbitrage Sa. Commercial Bank Of Ny Mellon invested in 0% or 105,291 shares.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $201.15 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

More notable recent Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) news were published by: Benzinga.com which released: “Jefferies Sees Opportunity In Marinus Pharmaceuticals (NASDAQ:MRNS): 4 Reasons Why – Benzinga” on March 05, 2019, also Globenewswire.com with their article: “Marinus Announces Leadership Transition Nasdaq:MRNS – GlobeNewswire” published on February 26, 2019, Nasdaq.com published: “Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference – Nasdaq” on February 20, 2019. More interesting news about Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were released by: Seekingalpha.com and their article: “Cowen sees 94% upside in Aurora Cannabis in premarket analyst action – Seeking Alpha” published on March 05, 2019 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For March 5, 2019 – Benzinga” with publication date: March 05, 2019.

Since January 28, 2019, it had 0 buys, and 2 selling transactions for $33,110 activity. Shares for $25,484 were sold by Cashman Christopher Michael on Monday, January 28. $7,626 worth of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was sold by Smith Edward F.

Among 5 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Marinus Pharmaceuticals had 9 analyst reports since February 6, 2019 according to SRatingsIntel. Ladenburg maintained the stock with “Buy” rating in Wednesday, March 6 report. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, March 6. The firm has “Hold” rating by Mizuho given on Tuesday, March 12. The rating was maintained by Ladenburg on Wednesday, February 27 with “Buy”. The firm has “Neutral” rating by Mizuho given on Wednesday, February 27. The firm has “Buy” rating given on Tuesday, March 12 by JMP Securities.

GameStop Corp. (NYSE:GME) Institutional Positions Chart